Skip to main content
NASDAQ:UTMD

Utah Medical Products Competitors

$88.50
+1.01 (+1.15 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$88.01
$89.18
50-Day Range
$84.99
$89.39
52-Week Range
$77.22
$109.00
Volume5,734 shs
Average Volume10,366 shs
Market Capitalization$322.67 million
P/E Ratio27.92
Dividend Yield1.30%
Beta0.29

Competitors

Utah Medical Products (NASDAQ:UTMD) Vs. ALGN, WST, COO, XRAY, STAA, and QDEL

Should you be buying UTMD stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Utah Medical Products, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), STAAR Surgical (STAA), and Quidel (QDEL).

Utah Medical Products (NASDAQ:UTMD) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Utah Medical Products has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Utah Medical Products and Align Technology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Utah Medical Products0000N/A
Align Technology111002.75

Align Technology has a consensus target price of $627.0909, indicating a potential upside of 10.20%. Given Align Technology's higher possible upside, analysts plainly believe Align Technology is more favorable than Utah Medical Products.

Profitability

This table compares Utah Medical Products and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Utah Medical Products27.97%11.48%10.54%
Align Technology76.00%68.99%46.64%

Insider and Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by insiders. Comparatively, 1.2% of Align Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Utah Medical Products and Align Technology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Utah Medical Products$46.90 million6.88$14.73 millionN/AN/A
Align Technology$2.41 billion18.71$442.78 million$4.96114.73

Align Technology has higher revenue and earnings than Utah Medical Products.

Summary

Align Technology beats Utah Medical Products on 10 of the 12 factors compared between the two stocks.

Utah Medical Products (NASDAQ:UTMD) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Dividends

Utah Medical Products pays an annual dividend of $1.14 per share and has a dividend yield of 1.3%. West Pharmaceutical Services pays an annual dividend of $0.68 per share and has a dividend yield of 0.2%. West Pharmaceutical Services pays out 21.0% of its earnings in the form of a dividend. Utah Medical Products has increased its dividend for 1 consecutive years and West Pharmaceutical Services has increased its dividend for 25 consecutive years.

Risk & Volatility

Utah Medical Products has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Utah Medical Products and West Pharmaceutical Services, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Utah Medical Products0000N/A
West Pharmaceutical Services01202.67

West Pharmaceutical Services has a consensus target price of $310.00, indicating a potential downside of 6.93%. Given West Pharmaceutical Services' higher possible upside, analysts plainly believe West Pharmaceutical Services is more favorable than Utah Medical Products.

Profitability

This table compares Utah Medical Products and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Utah Medical Products27.97%11.48%10.54%
West Pharmaceutical Services14.69%19.01%12.78%

Insider and Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by company insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Utah Medical Products and West Pharmaceutical Services' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Utah Medical Products$46.90 million6.88$14.73 millionN/AN/A
West Pharmaceutical Services$1.84 billion13.36$241.70 million$3.24102.80

West Pharmaceutical Services has higher revenue and earnings than Utah Medical Products.

Summary

West Pharmaceutical Services beats Utah Medical Products on 11 of the 15 factors compared between the two stocks.

Utah Medical Products (NASDAQ:UTMD) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Dividends

Utah Medical Products pays an annual dividend of $1.14 per share and has a dividend yield of 1.3%. The Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. The Cooper Companies pays out 0.6% of its earnings in the form of a dividend. Utah Medical Products has increased its dividend for 1 consecutive years and The Cooper Companies has increased its dividend for 1 consecutive years.

Risk & Volatility

Utah Medical Products has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Utah Medical Products and The Cooper Companies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Utah Medical Products0000N/A
The Cooper Companies04702.64

The Cooper Companies has a consensus target price of $385.50, indicating a potential downside of 0.95%. Given The Cooper Companies' higher possible upside, analysts plainly believe The Cooper Companies is more favorable than Utah Medical Products.

Profitability

This table compares Utah Medical Products and The Cooper Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Utah Medical Products27.97%11.48%10.54%
The Cooper Companies9.81%12.79%7.20%

Insider and Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by company insiders. Comparatively, 1.4% of The Cooper Companies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Utah Medical Products and The Cooper Companies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Utah Medical Products$46.90 million6.88$14.73 millionN/AN/A
The Cooper Companies$2.43 billion7.87$238.40 million$9.6440.37

The Cooper Companies has higher revenue and earnings than Utah Medical Products.

Summary

The Cooper Companies beats Utah Medical Products on 9 of the 14 factors compared between the two stocks.

Utah Medical Products (NASDAQ:UTMD) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Dividends

Utah Medical Products pays an annual dividend of $1.14 per share and has a dividend yield of 1.3%. DENTSPLY SIRONA pays an annual dividend of $0.40 per share and has a dividend yield of 0.6%. DENTSPLY SIRONA pays out 16.3% of its earnings in the form of a dividend. Utah Medical Products has increased its dividend for 1 consecutive years and DENTSPLY SIRONA has increased its dividend for 1 consecutive years.

Risk & Volatility

Utah Medical Products has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Utah Medical Products and DENTSPLY SIRONA, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Utah Medical Products0000N/A
DENTSPLY SIRONA13602.50

DENTSPLY SIRONA has a consensus target price of $62.4444, indicating a potential downside of 7.94%. Given DENTSPLY SIRONA's higher possible upside, analysts plainly believe DENTSPLY SIRONA is more favorable than Utah Medical Products.

Profitability

This table compares Utah Medical Products and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Utah Medical Products27.97%11.48%10.54%
DENTSPLY SIRONA-1.40%7.13%4.13%

Insider and Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Utah Medical Products and DENTSPLY SIRONA's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Utah Medical Products$46.90 million6.88$14.73 millionN/AN/A
DENTSPLY SIRONA$4.03 billion3.68$262.90 million$2.4527.69

DENTSPLY SIRONA has higher revenue and earnings than Utah Medical Products.

Summary

Utah Medical Products beats DENTSPLY SIRONA on 8 of the 14 factors compared between the two stocks.

Utah Medical Products (NASDAQ:UTMD) and STAAR Surgical (NASDAQ:STAA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Utah Medical Products has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Profitability

This table compares Utah Medical Products and STAAR Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Utah Medical Products27.97%11.48%10.54%
STAAR Surgical5.73%8.99%7.12%

Valuation and Earnings

This table compares Utah Medical Products and STAAR Surgical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Utah Medical Products$46.90 million6.88$14.73 millionN/AN/A
STAAR Surgical$150.18 million34.56$14.05 million$0.46240.61

Utah Medical Products has higher earnings, but lower revenue than STAAR Surgical.

Analyst Ratings

This is a breakdown of recent recommendations for Utah Medical Products and STAAR Surgical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Utah Medical Products0000N/A
STAAR Surgical03302.50

STAAR Surgical has a consensus target price of $78.40, indicating a potential downside of 29.17%. Given STAAR Surgical's higher possible upside, analysts plainly believe STAAR Surgical is more favorable than Utah Medical Products.

Insider and Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by insiders. Comparatively, 3.9% of STAAR Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

STAAR Surgical beats Utah Medical Products on 7 of the 12 factors compared between the two stocks.

Utah Medical Products (NASDAQ:UTMD) and Quidel (NASDAQ:QDEL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.

Volatility and Risk

Utah Medical Products has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.

Profitability

This table compares Utah Medical Products and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Utah Medical Products27.97%11.48%10.54%
Quidel36.91%63.31%40.55%

Earnings & Valuation

This table compares Utah Medical Products and Quidel's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Utah Medical Products$46.90 million6.88$14.73 millionN/AN/A
Quidel$534.89 million9.40$72.92 million$2.7343.30

Quidel has higher revenue and earnings than Utah Medical Products.

Analyst Recommendations

This is a breakdown of recent ratings for Utah Medical Products and Quidel, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Utah Medical Products0000N/A
Quidel10302.50

Quidel has a consensus target price of $182.75, indicating a potential upside of 54.60%. Given Quidel's higher possible upside, analysts plainly believe Quidel is more favorable than Utah Medical Products.

Insider & Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 84.0% of Quidel shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by insiders. Comparatively, 14.1% of Quidel shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Quidel beats Utah Medical Products on 11 of the 12 factors compared between the two stocks.


Utah Medical Products Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
2.1$569.04+2.7%$45.03 billion$2.41 billion25.89
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$333.07+1.4%$24.59 billion$1.84 billion87.88
The Cooper Companies logo
COO
The Cooper Companies
1.9$389.19+0.3%$19.13 billion$2.43 billion80.91
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$67.83+1.8%$14.81 billion$4.03 billion-294.91Analyst Report
STAAR Surgical logo
STAA
STAAR Surgical
1.4$110.68+4.0%$5.19 billion$150.18 million582.56Analyst Report
Insider Selling
Quidel logo
QDEL
Quidel
2.4$118.21+1.4%$5.03 billion$534.89 million13.87Analyst Report
Insider Selling
Neogen logo
NEOG
Neogen
1.2$92.86+0.8%$4.97 billion$418.17 million81.46Stock Split
ICU Medical logo
ICUI
ICU Medical
1.5$199.00+1.8%$4.22 billion$1.27 billion52.65Insider Selling
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.7$59.69+0.0%$3.34 billion$994.85 million-112.62
Haemonetics logo
HAE
Haemonetics
2.2$56.00+7.5%$2.85 billion$988.48 million27.05Earnings Announcement
Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Atrion logo
ATRI
Atrion
1.1$600.39+0.6%$1.10 billion$155.07 million33.82
Cerus logo
CERS
Cerus
1.7$5.75+3.5%$984.24 million$74.65 million-14.74
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$19.07+2.5%$826.30 million$253.67 million17.66Analyst Revision
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$9.51+1.9%$684.34 million$154.60 million-41.35Analyst Downgrade
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.00+4.8%$675.19 million$123.86 million66.68News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$43.68+2.3%$628.60 million$114.51 million-92.94
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.